汽车结合剂会影响汽车T细胞的调性信号,耐久性和对目标的敏感性
Divanshu Shukla1,2, Khatuna Gabunia2,3, Shannon E McGettigan2,3
1Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania.
Cancer immunology research
|April 29, 2025
概括
研究人员开发出完全人类的CD19特异性仿制抗原受体 (CAR) T细胞,以克服抗老鼠免疫反应. 结合物42 CAR T 细胞的疗效与现有疗法相比较,表明其临床潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 在CAR-T细胞中,小鼠CD19特定的单链变量片段可以引起抗小鼠免疫反应.
- 开发完全人类的CAR T细胞对于减轻免疫性和改善治疗结果至关重要.
研究的目的:
- 为了识别和选择完全人类的CD19结合剂用于CAR T细胞治疗.
- 与现有疗法相比,评估全人类新型CAR T细胞的疗效和安全性.
主要方法:
- 对酵母展示库的选,以识别完全人类的CD19结合剂.
- 在体外和体内研究,以评估CAR T细胞功能,包括瘤杀死和抗原识别.
- 在急性淋巴细胞白血病的小鼠模型中进行临床前测试.
主要成果:
- 确定了多个完全人类的CD19结合剂,具有不同的CAR T细胞性能特征.
- 使用结合剂42的CAR T细胞在体内表现出强大的抗瘤活性和与基于FMC63的CAR T细胞相比的有效性.
- 在急性淋巴细胞白血病的小鼠模型中,结合剂42 CAR T 细胞显示非劣于 FMC63 CAR T 细胞.
结论:
- 使用结合剂42的全人类CD19特异性CAR T细胞为基于小鼠的CAR T细胞提供了一个有希望的替代品.
- 结合物42的CAR T细胞表现出与已确定的疗法相比的疗效,需要进一步的临床研究.
- 这种方法可以克服与当前CAR T细胞疗法相关的免疫性问题.
相关概念视频
T Cell Activation and Clonal Selection
526
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
526
B Cell Activation and Differentiation
1.2K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.2K
Intracellular Signaling Affects Focal Adhesions
2.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.5K
Drug Distribution: Tissue Binding
2.4K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.4K
The Equilibrium Binding Constant and Binding Strength
12.7K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
12.7K
Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397


